A Phase 3 interventional study of Emicizumab and rFVIIa in Hemophilia A, sponsored by Hoffmann-La Roche. Completed at 44 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-06-24.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing emicizumab in Hemophilia A — 6 open to participants now, 8 under way, 3 of them phase 3. emicizumab · Hemophilia A.
Among the 22 studies testing emicizumab in Hemophilia A, this one is the 4th largest by enrollment, is the only one that started in 2015, is one of 11 in phase 3, and was the 1st registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →6 of the 22 studies testing emicizumab in Hemophilia A are open now, in 4 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Taiwan
Ages 12+ · Men only
Chulalongkorn University · Sites in Thailand
Ages 3–30 · Men only · Healthy volunteers
Bleeding and Clotting Disorders Institute Peoria, Illinois · Sites in United States
Ages 0–90
Indiana Hemophilia &Thrombosis Center, Inc. · Sites in United States
Ages 5–45 · Men only
Versiti Blood Health · Sites in United States
Ages 0–17
By country, each count listing its studies:
emicizumab: first FDA approval 2017 (HEMLIBRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 13 · Phase 4 6
First in 2015; this study’s year is marked. 1 started in 2015.
This study's enrollment of 113 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 27 across the 22 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 22 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
25 studies in Hemophilia A by Hoffmann-La Roche: 5 open now, 8 under way, 4 of them phase 3. Of 15 finished, 12 (80%) have results posted.
Among the 25 studies in Hemophilia A by Hoffmann-La Roche, this one is the 6th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2015, is one of 12 in phase 3, and was the 3rd registered.
Hoffmann-La Roche’s Hemophilia A studies by the year they started, since 2012.
2 of the studies testing emicizumab in Hemophilia A that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05181618Hoffmann-La RocheA Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis | 2026-11-19 |
| NCT05500807Bleeding and Clotting Disorders Institute Peoria, IllinoisEmicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing emicizumab in Hemophilia A, from their registry updates:
Among Hoffmann-La Roche’s 25 in Hemophilia A:
This tab as a report to print or save as PDF → With an account.
This multicenter, open-label study will evaluate the safety, efficacy and pharmacokinetics of prophylactic emicizumab treatment in participants previously treated with episodic or prophylactic bypassing agents. Episodic bypassing agent participants will be randomized in a 2:1 fashion to receive emicizumab prophylaxis (Arm A) versus no prophylaxis (Arm B) and will be stratified across Arms A and B according to the number of bleeds they experienced over the last 24 weeks prior to study entry (less than [\<] 9 or greater than or equal to [>/=] 9 bleeds); Arm B participants will have the opportunity to switch to emicizumab prophylaxis after at least 24 weeks on-study. Prophylactic bypassing agent participants will switch to emicizumab prophylaxis (Arm C) from the start of the trial; enrollment will be extended for 24 weeks after the last participant has enrolled in Arms A or B or until approximately 50 participants have enrolled in Arm C, whichever occurs first. Episodic bypassing agent participants who previously participated in the non-interventional study BH29768 (NCT02476942) who were unable to enroll in Arms A or B, or participants on prophylactic bypassing agents who were unable to enroll in Arm C, prior to their closure will have the opportunity to enroll in Arm D. Like participants in Arms A and C, Arm D participants will receive emicizumab prophylaxis from the start of the trial. All participants will continue to receive episodic bypassing agent therapy to treat breakthrough bleeds, preferably with recombinant activated factor VII (rFVIIa).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm A started to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 milligrams per kilogram (mg/kg) once a week (QW) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
Drug: Emicizumab · Drug: rFVIIa · Drug: aPCC
Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm B continued with their prior episodic treatment regimen for the first 24 weeks of the study; they did not receive emicizumab prophylaxis during that time. After completing at least 24 weeks on study, participants in Arm B were allowed to switch to emicizumab prophylaxis (as described for Arm A) up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
Drug: Emicizumab · Drug: rFVIIa · Drug: aPCC
Participants who were receiving prophylactic bypassing agents prior to study entry were enrolled in Arm C to receive prophylactic emicizumab. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
Drug: Emicizumab · Drug: rFVIIa · Drug: aPCC
Participants who were either: 1) Receiving episodic bypassing agents prior to study entry but were unable to enroll in Arms A or B; or 2) Receiving bypassing agent prophylaxis prior to study entry but were unable to enroll in Arm C, were enrolled in Arm D to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
Drug: Emicizumab · Drug: rFVIIa · Drug: aPCC
Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study. After at least 24 weeks on prophylactic emicizumab, individuals who experience suboptimal bleeding control on emicizumab (according to protocol-defined criteria) will have the opportunity to increase their dose to 3 mg/kg weekly.
Also known as: Hemlibra, RO5534262, RG6013, ACE910
Participants will continue to receive rFVIIa.
Also known as: NovoSeven®
Participants will continue to receive aPCC.
Also known as: Factor Eight Inhibitor Bypassing Activity (FEIBA®)
Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
The number of treated bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds were defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Model-Based Annualized Bleed Rate (ABR) for All Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
The number of all bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents
This was an intra-participant comparison of the annualized bleed rates (ABRs) for all bleeds in Arm A participants who had previously received episodic bypassing agents during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm A NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm A). The number of all bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
Time frame: Median [min-max] efficacy observation periods: for Arm A, 1.5 mg/kg Emicizumab QW: 30.86 [0.1-48.9] weeks; for Arm A (NIS), Previous Episodic Bypassing Agents: 21.14 [10.6-33.9] weeks
Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents
This was an intra-participant comparison of the ABRs for treated bleeds in Arm A participants who had previously received episodic bypassing agents during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm A NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm A). The number of treated bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds were defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, efficacy period ended the day before the first day on the up-titrated dose.
Time frame: Median [min-max] efficacy observation periods: for Arm A, 1.5 mg/kg Emicizumab QW: 30.86 [0.1-48.9] weeks; for Arm A (NIS), Previous Episodic Bypassing Agents: 21.14 [10.6-33.9] weeks
Model-Based Annualized Bleed Rate (ABR) for Treated Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
The number of treated joint bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated joint bleeds were defined as treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Bleeds due to surgery/procedure were excluded.
Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents
This was an intra-participant comparison of the annualized bleed rates (ABRs) for all bleeds in Arm C participants who had previously received prophylactic bypassing agents during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm C NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm C). The number of all bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
Time frame: Median [min-max] efficacy observation periods: for Arm C, 1.5 mg/kg Emicizumab QW: 30.14 [6.9-45.3] weeks; for Arm C (NIS), Previous Prophylactic Bypassing Agents: 32.14 [8.1-49.3] weeks
Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents
This was an intra-participant comparison of the ABRs for treated bleeds in Arm C participants who had previously received bypassing agent prophylaxis during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm C NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm C). The number of treated bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds were defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, efficacy period ended the day before the first day on the up-titrated dose.
Time frame: Median [min-max] efficacy observation periods: for Arm C, 1.5 mg/kg Emicizumab QW: 30.14 [6.9-45.3] weeks; for Arm C (NIS), Previous Prophylactic Bypassing Agents: 32.14 [8.1-49.3] weeks
Model-Based Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
The number of treated spontaneous bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Model-Based Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
The number of treated target joint bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated target joint bleeds included treated (with coagulation factors) joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.
Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.
Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Percentage of Participants With 0 Bleeds for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis
Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.
Time frame: From Baseline up to 24 weeks (median [min-max] efficacy observation periods in Arm A vs. Arm B: 29.29 [0.1-48.9] weeks vs. 24.14 [23.0-26.0] weeks)
Hemophilia-Specific Quality of Life (Haem-A-QoL) Questionnaire Physical Health Score at Week 25 in Adult Participants (>/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis
Haem-A-QoL questionnaire has been developed and used in hemophilia A participants. As a hemophilia-specific questionnaire, this measure assesses very specific aspects of dealing with hemophilia. This questionnaire consists of items pertaining to 10 domains specific to living with hemophilia. The 10 domains are: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain range from 0 to 100 with lower scores reflective of better quality of life. Physical Health domain score is reported (range 0 to 100, with lower scores reflective of better physical health).
Time frame: Week 25
Haem-A-QoL Questionnaire Total Score at Week 25 in Adult Participants (>/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis
Haem-A-QoL questionnaire has been developed and used in hemophilia A participants. As a hemophilia-specific questionnaire, this measure assesses very specific aspects of dealing with hemophilia. This questionnaire consists of items pertaining to 10 domains specific to living with hemophilia. The 10 domains are: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain range from 0 to 100 with lower scores reflective of better quality of life. Haem-A-QoL Questionnaire Total Score is the average of the all domain scores and range from 0 to 100, with lower scores reflective of better quality of life.
Time frame: Week 25
European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analog Scale Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.
Time frame: Week 25
EQ-5D-5L Index Utility Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The EQ-5D-5L health state profile is designed to record the participant's current health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses from the five domains are used to calculate a single utility index value ranging from 1 to 5, where 1 indicates better health state (no problems) and 5 indicates worst health state (confined to bed).
Time frame: Week 25
Hemophilia-Specific Quality of Life - Short Form (Haemo-Qol-SF) Questionnaire Total Score at Baseline and Week 25 in Adolescent Participants (12-17 Years Old)
The Haemo-QoL-SF contains 35 items, which cover nine domains considered relevant for the children's health-related quality of life (physical health, feelings, view of yourself, family, friends, other people, sports and school, dealing with hemophilia and treatment). Items are rated with five respective response options: never, seldom, sometimes, often, and always. Haemo-QoL-SF total score range from 0 to 100, where lower scores reflect better health-related quality of life. Baseline was defined as the last assessment prior to treatment. Because participants in Arm B switched from episodic bypassing agents to start receiving emicizumab prophylaxis after Week 24, the timepoints for Arm B (Emi) are expressed relative to first emicizumab dose; baseline for Arm B (Emi) is the same as Week 25 for Arm B (Control).
Time frame: Baseline and Week 25 (for Arm B (Emi), Study Weeks are relative to first emicizumab dose)
Long-Term Efficacy of Emicizumab: Model-Based Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants
The number of bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.
Time frame: From start of emicizumab treatment to study completion (median [min-max] efficacy observation period for all participants: 109.29 [0.1-249.1] weeks)
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.
Time frame: From start of emicizumab treatment to study completion (median [min-max] efficacy observation period for all participants: 109.29 [0.1-249.1] weeks)
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds, All Enrolled Participants
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.
Time frame: From start of emicizumab treatment to study completion (median [min-max] efficacy observation period for all participants: 109.29 [0.1-249.1] weeks)
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants
The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants
The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants
The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants
The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants
The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleed Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time, All Enrolled Participants
The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, and 229-240 weeks
Safety Summary of the Overall Number and Percentage of Participants With at Least One Adverse Event, Severity Assessed According to the WHO Toxicity Grading Scale
Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. For participants whose emicizumab dose was up-titrated, only data before up-titration is included. aPCC = activated prothrombin complex concentrate; Hypersens.= hypersensitivity
Time frame: From Baseline until study completion (median [min-max] safety observation period for all participants: 133.97 [0.1-249.1] weeks)
Number of Participants Testing Negative or Positive for the Presence of Anti-Drug Antibodies (ADAs), Including Neutralizing ADAs, During the Study
'Total ADA Negative' is the sum of all subjects who tested negative for ADA in the 2 following categories: 'ADA Negative', those who are pre-dose ADA negative or are missing pre-dose ADA data and who have all negative post-dose ADA results; and 'ADA Negative (Treatment Unaffected)', a subset who are pre-dose ADA positive but do not have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement. 'Total ADA Positive' is the sum of all subjects who tested positive for ADA in the 2 following categories: 'ADA Positive (Treatment Boosted)', those who are pre-dose ADA positive and have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement; and 'ADA Positive (Treatment Induced)', those who are pre-dose ADA negative or missing data and who have at least one post-dose ADA positive sample. ADA-positive samples were further analyzed for neutralizing capacity using a modified FVIII chromogenic assay; if also positive, they were considered neutralizing ADAs.
Time frame: From Baseline until study completion (median [min-max] safety observation period for all participants: 133.97 [0.1-249.1] weeks)
Plasma Trough Concentrations of Emicizumab at Specified Timepoints
Plasma concentrations of emicizumab were analyzed using a validated Enzyme Linked Immunosorbent Assay (ELISA). The lower limit of quantification (LLOQ) was 100 nanograms per milliliter (ng/mL). Because participants in Arm B switched from episodic bypassing agents to start receiving emicizumab prophylaxis after Week 24, the timepoints for Arm B (Emi) are expressed relative to first emicizumab dose.
Time frame: Pre-dose (0 hour [hr]) on Weeks 1-5, 7, 9, 13, 17, 21, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157, and 169 (For Arm B (Emi), Study Weeks are relative to first emicizumab dose)
| Milestone | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis, Then Emicizumab | Arm C: 1.5 mg/kg Emicizumab QW | Arm D: 1.5 mg/kg Emicizumab QW |
|---|---|---|---|---|
| Started | 35 | 18 | 49 | 11 |
| Received at least one dose of treatment | 34 | 18 | 49 | 11 |
| Completed 24 weeks in the study | 31 | 18 | 49 | 11 |
| Dose up-titrated to 3 mg/kg qw | 2 | 0 | 3 | 2 |
| Completed | 32 | 18 | 48 | 11 |
| Not completed | 3 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
The number of treated bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds were defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
| treated bleeds per year | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis |
|---|---|---|
| Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis | 2.9 (1.69 to 5.02) | 23.3 (12.33 to 43.89) |
The number of all bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
| all bleeds per year | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis |
|---|---|---|
| Model-Based Annualized Bleed Rate (ABR) for All Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis | 5.5 (3.58 to 8.60) | 28.3 (16.79 to 47.76) |
This was an intra-participant comparison of the annualized bleed rates (ABRs) for all bleeds in Arm A participants who had previously received episodic bypassing agents during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm A NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm A). The number of all bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
| all bleeds per year | Arm A: 1.5 mg/kg Emicizumab QW | Arm A (NIS): Previous Episodic Bypassing Agents |
|---|---|---|
| Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents | 4.1 (2.10 to 8.02) | 37.7 (28.40 to 50.04) |
This was an intra-participant comparison of the ABRs for treated bleeds in Arm A participants who had previously received episodic bypassing agents during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm A NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm A). The number of treated bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds were defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, efficacy period ended the day before the first day on the up-titrated dose.
| treated bleeds per year | Arm A: 1.5 mg/kg Emicizumab QW | Arm A (NIS): Previous Episodic Bypassing Agents |
|---|---|---|
| Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm A: Emicizumab Versus Previous Episodic Bypassing Agents | 1.7 (0.71 to 4.06) | 21.6 (15.40 to 30.22) |
The number of treated joint bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated joint bleeds were defined as treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Bleeds due to surgery/procedure were excluded.
| treated joint bleeds per year | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis |
|---|---|---|
| Model-Based Annualized Bleed Rate (ABR) for Treated Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis | 0.8 (0.26 to 2.20) | 6.7 (1.99 to 22.42) |
This was an intra-participant comparison of the annualized bleed rates (ABRs) for all bleeds in Arm C participants who had previously received prophylactic bypassing agents during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm C NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm C). The number of all bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
| all bleeds per year | Arm C: 1.5 mg/kg Emicizumab QW | Arm C (NIS): Previous Prophylactic Bypassing Agents |
|---|---|---|
| Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for All Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents | 5.5 (2.98 to 10.26) | 24.3 (18.11 to 32.67) |
This was an intra-participant comparison of the ABRs for treated bleeds in Arm C participants who had previously received bypassing agent prophylaxis during the non-interventional study (NIS) BH29768 (NCT02476942) (Arm C NIS) prior to entry in this study versus emicizumab prophylaxis during this study (Arm C). The number of treated bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds were defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, efficacy period ended the day before the first day on the up-titrated dose.
| treated bleeds per year | Arm C: 1.5 mg/kg Emicizumab QW | Arm Cnis: Previous Prophylactic Bypassing Agents |
|---|---|---|
| Intra-Participant Comparison of the Model-Based Annualized Bleed Rate (ABR) for Treated Bleeds in Arm C: Emicizumab Versus Previous Prophylactic Bypassing Agents | 3.3 (1.33 to 8.08) | 15.7 (11.08 to 22.29) |
The number of treated spontaneous bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
| treated spontaneous bleeds per year | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis |
|---|---|---|
| Model-Based Annualized Bleed Rate (ABR) for Treated Spontaneous Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis | 1.3 (0.73 to 2.19) | 16.8 (9.94 to 28.30) |
The number of treated target joint bleeds over the efficacy period was assessed as an annualized bleed rate (ABR) using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated target joint bleeds included treated (with coagulation factors) joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
| treated target joint bleeds per year | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis |
|---|---|---|
| Model-Based Annualized Bleed Rate (ABR) for Treated Target Joint Bleeds, Arm A: Emicizumab Versus Arm B: No Prophylaxis | 0.1 (0.03 to 0.58) | 3.0 (0.96 to 9.13) |
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.
| bleeds per year | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis |
|---|---|---|
| Treated Bleeds | 3.5 (0.83 to 9.46) | 26.2 (17.17 to 38.37) |
| All Bleeds | 6.3 (2.37 to 13.45) | 30.8 (20.89 to 43.76) |
| Treated Spontaneous Bleeds | 1.5 (0.11 to 6.42) | 18.1 (10.74 to 28.57) |
| Treated Joint Bleeds | 1.0 (0.03 to 5.57) | 8.1 (3.55 to 15.95) |
| Treated Target Joint Bleeds | 0.4 (0.00 to 4.48) | 6.2 (2.32 to 13.34) |
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.
| bleeds per year | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis |
|---|---|---|
| Treated Bleeds | 0.0 (0.00 to 3.73) | 18.8 (12.97 to 35.08) |
| All Bleeds | 2.0 (0.00 to 9.87) | 30.2 (18.26 to 39.37) |
| Treated Spontaneous Bleeds | 0.0 (0.00 to 3.28) | 15.2 (6.64 to 30.44) |
| Treated Joint Bleeds | 0.0 (0.00 to 0.00) | 1.0 (0.00 to 14.44) |
| Treated Target Joint Bleeds | 0.0 (0.00 to 0.00) | 1.0 (0.00 to 6.52) |
Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.
| Percentage of participants | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis |
|---|---|---|
| Treated Bleeds | 62.9 (44.9 to 78.5) | 5.6 (0.1 to 27.3) |
| All Bleeds | 37.1 (21.5 to 55.1) | 5.6 (0.1 to 27.3) |
| Treated Spontaneous Bleeds | 68.6 (50.7 to 83.1) | 11.1 (1.4 to 34.7) |
| Treated Joint Bleeds | 85.7 (69.7 to 95.2) | 50.0 (26.0 to 74.0) |
| Treated Target Joint Bleeds | 94.3 (80.8 to 99.3) | 50.0 (26.0 to 74.0) |
Haem-A-QoL questionnaire has been developed and used in hemophilia A participants. As a hemophilia-specific questionnaire, this measure assesses very specific aspects of dealing with hemophilia. This questionnaire consists of items pertaining to 10 domains specific to living with hemophilia. The 10 domains are: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain range from 0 to 100 with lower scores reflective of better quality of life. Physical Health domain score is reported (range 0 to 100, with lower scores reflective of better physical health).
| score on a scale | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis |
|---|---|---|
| Hemophilia-Specific Quality of Life (Haem-A-QoL) Questionnaire Physical Health Score at Week 25 in Adult Participants (>/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis | 30.19 ± 26.59 | 57.14 ± 23.35 |
Haem-A-QoL questionnaire has been developed and used in hemophilia A participants. As a hemophilia-specific questionnaire, this measure assesses very specific aspects of dealing with hemophilia. This questionnaire consists of items pertaining to 10 domains specific to living with hemophilia. The 10 domains are: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain range from 0 to 100 with lower scores reflective of better quality of life. Haem-A-QoL Questionnaire Total Score is the average of the all domain scores and range from 0 to 100, with lower scores reflective of better quality of life.
| score on a scale | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis |
|---|---|---|
| Haem-A-QoL Questionnaire Total Score at Week 25 in Adult Participants (>/=18 Years Old), Arm A: Emicizumab Versus Arm B: No Prophylaxis | 26.465 ± 18.666 | 47.504 ± 17.435 |
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.
| score on a scale | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis |
|---|---|---|
| European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analog Scale Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis | 83.8 ± 12.9 | 76.4 ± 15.7 |
EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L Visual Analog Scale. The EQ-5D-5L health state profile is designed to record the participant's current health state in 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses from the five domains are used to calculate a single utility index value ranging from 1 to 5, where 1 indicates better health state (no problems) and 5 indicates worst health state (confined to bed).
| score on a scale | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis |
|---|---|---|
| EQ-5D-5L Index Utility Score at Week 25, Arm A: Emicizumab Versus Arm B: No Prophylaxis | 0.83 ± 0.22 | 0.60 ± 0.35 |
The Haemo-QoL-SF contains 35 items, which cover nine domains considered relevant for the children's health-related quality of life (physical health, feelings, view of yourself, family, friends, other people, sports and school, dealing with hemophilia and treatment). Items are rated with five respective response options: never, seldom, sometimes, often, and always. Haemo-QoL-SF total score range from 0 to 100, where lower scores reflect better health-related quality of life. Baseline was defined as the last assessment prior to treatment. Because participants in Arm B switched from episodic bypassing agents to start receiving emicizumab prophylaxis after Week 24, the timepoints for Arm B (Emi) are expressed relative to first emicizumab dose; baseline for Arm B (Emi) is the same as Week 25 for Arm B (Control).
| units on a scale | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis | Arm B (Emi): 1.5 mg/kg Emicizumab QW | Arm C: 1.5 mg/kg Emicizumab QW |
|---|---|---|---|---|
| Baseline | 34.643 ± 22.728 | 37.143 ± 12.122 | 30.000 ± 14.142 | 30.714 ± 15.625 |
| Week 25 | 33.095 ± 17.559 | 30.000 ± 14.142 | 12.143 ± 7.071 | 19.286 ± 14.507 |
The number of bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.
| bleeds per year | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Emi): 1.5 mg/kg Emicizumab QW | Arm C: 1.5 mg/kg Emicizumab QW | Arm D: 1.5 mg/kg Emicizumab QW | All Participants: 1.5 mg/kg Emicizumab QW |
|---|---|---|---|---|---|
| Treated Bleeds | 1.9 (1.02 to 3.53) | 0.6 (0.22 to 1.36) | 3.2 (1.51 to 6.65) | 1.5 (0.20 to 11.72) | 2.4 (1.50 to 3.82) |
| All Bleeds | 3.5 (2.11 to 5.74) | 1.3 (0.66 to 2.39) | 4.3 (2.43 to 7.77) | 2.3 (0.79 to 6.77) | 3.6 (2.55 to 5.13) |
| Treated Spontaneous Bleeds | 0.6 (0.33 to 1.26) | 0.1 (0.06 to 0.29) | 2.1 (0.89 to 4.80) | 0.8 (0.07 to 9.16) | 1.3 (0.76 to 2.18) |
| Treated Joint Bleeds | 0.5 (0.16 to 1.69) | 0.1 (0.04 to 0.31) | 0.4 (0.14 to 0.96) | 0.4 (0.05 to 3.41) | 0.4 (0.21 to 0.82) |
| Treated Target Joint Bleeds | 0.1 (0.01 to 0.31) | 0.01 (0.01 to 0.18) | 0.3 (0.09 to 0.84) | 0.3 (0.04 to 2.36) | 0.2 (0.10 to 0.57) |
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.
| bleeds per year | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Emi): 1.5 mg/kg Emicizumab QW | Arm C: 1.5 mg/kg Emicizumab QW | Arm D: 1.5 mg/kg Emicizumab QW | All Participants: 1.5 mg/kg Emicizumab QW |
|---|---|---|---|---|---|
| Treated Bleeds | 2.9 (0.58 to 8.63) | 0.6 (0.00 to 4.85) | 3.3 (0.77 to 9.28) | 1.6 (0.14 to 6.61) | 2.6 (0.46 to 8.16) |
| All Bleeds | 4.8 (1.49 to 11.33) | 1.3 (0.07 to 6.11) | 4.6 (1.40 to 11.09) | 2.5 (0.42 to 8.02) | 3.9 (1.05 to 10.13) |
| Treated Spontaneous Bleeds | 1.2 (0.06 to 5.99) | 0.2 (0.00 to 4.01) | 2.2 (0.32 to 7.59) | 0.9 (0.01 to 5.33) | 1.5 (0.10 to 6.35) |
| Treated Joint Bleeds | 0.9 (0.02 to 5.42) | 0.1 (0.00 to 3.95) | 0.4 (0.00 to 4.53) | 0.4 (0.00 to 4.56) | 0.5 (0.00 to 4.73) |
| Treated Target Joint Bleeds | 0.4 (0.00 to 4.44) | 0.1 (0.00 to 3.79) | 0.3 (0.00 to 4.35) | 0.4 (0.00 to 4.40) | 0.3 (0.00 to 4.30) |
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (\>/=) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration were excluded.
| bleeds per year | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Emi): 1.5 mg/kg Emicizumab QW | Arm C: 1.5 mg/kg Emicizumab QW | Arm D: 1.5 mg/kg Emicizumab QW | All Participants: 1.5 mg/kg Emicizumab QW |
|---|---|---|---|---|---|
| Treated Bleeds | 0.3 (0.00 to 2.05) | 0.0 (0.00 to 0.48) | 0.0 (0.00 to 1.13) | 0.0 (0.00 to 0.67) | 0.0 (0.00 to 1.09) |
| All Bleeds | 1.9 (0.22 to 5.13) | 0.5 (0.00 to 2.18) | 0.6 (0.00 to 2.25) | 0.5 (0.00 to 4.41) | 0.6 (0.00 to 3.34) |
| Treated Spontaneous Bleeds | 0.0 (0.00 to 0.87) | 0.0 (0.00 to 0.24) | 0.0 (0.00 to 0.47) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.51) |
| Treated Joint Bleeds | 0.0 (0.00 to 0.24) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) |
| Treated Target Joint Bleeds | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) | 0.0 (0.00 to 0.00) |
The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
| treated bleeds per year | All Participants: 1.5 mg/kg Emicizumab QW |
|---|---|
| 1 to 12 Weeks | 3.9 (1.05 to 10.12) |
| 13 to 24 Weeks | 2.2 (0.31 to 7.53) |
| 25 to 36 Weeks | 0.9 (0.01 to 5.31) |
| 37 to 48 Weeks | 0.3 (0.00 to 4.38) |
| 49 to 60 Weeks | 0.4 (0.00 to 4.56) |
| 61 to 72 Weeks | 0.5 (0.00 to 4.73) |
| 73 to 84 Weeks | 0.6 (0.00 to 4.80) |
| 85 to 96 Weeks | 0.4 (0.00 to 4.46) |
| 97 to 108 Weeks | 0.5 (0.00 to 4.71) |
| 109 to 120 Weeks | 0.0 (NA to 3.69) |
| 121 to 132 Weeks | 0.4 (0.00 to 4.48) |
| 133 to 144 Weeks | 0.5 (0.00 to 4.62) |
| 145 to 156 Weeks | 0.4 (0.00 to 4.53) |
| 157 to 168 Weeks | 0.2 (0.00 to 4.01) |
| 169 to 180 Weeks | 0.2 (0.00 to 4.08) |
| 181 to 192 Weeks | 0.0 (NA to 3.69) |
| 193 to 204 Weeks | 0.0 (NA to 3.69) |
| 205 to 216 Weeks | 0.0 (NA to 3.69) |
| 217 to 228 Weeks | 0.0 (NA to 3.69) |
| 229 to 240 Weeks | 0.0 (NA to 3.69) |
The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
| treated bleeds per year | All Participants: 1.5 mg/kg Emicizumab QW |
|---|---|
| 1 to 12 Weeks | 0.0 (0.00 to 4.35) |
| 13 to 24 Weeks | 0.0 (0.00 to 0.00) |
| 25 to 36 Weeks | 0.0 (0.00 to 0.00) |
| 37 to 48 Weeks | 0.0 (0.00 to 0.00) |
| 49 to 60 Weeks | 0.0 (0.00 to 0.00) |
| 61 to 72 Weeks | 0.0 (0.00 to 0.00) |
| 73 to 84 Weeks | 0.0 (0.00 to 0.00) |
| 85 to 96 Weeks | 0.0 (0.00 to 0.00) |
| 97 to 108 Weeks | 0.0 (0.00 to 0.00) |
| 109 to 120 Weeks | 0.0 (0.00 to 0.00) |
| 121 to 132 Weeks | 0.0 (0.00 to 0.00) |
| 133 to 144 Weeks | 0.0 (0.00 to 0.00) |
| 145 to 156 Weeks | 0.0 (0.00 to 0.00) |
| 157 to 168 Weeks | 0.0 (0.00 to 0.00) |
| 169 to 180 Weeks | 0.0 (0.00 to 0.00) |
| 181 to 192 Weeks | 0.0 (0.00 to 0.00) |
| 193 to 204 Weeks | 0.0 (0.00 to 0.00) |
| 205 to 216 Weeks | 0.0 (0.00 to 0.00) |
| 217 to 228 Weeks | 0.0 (0.00 to 0.00) |
| 229 to 240 Weeks | 0.0 (0.00 to 0.00) |
The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
| all bleeds per year | All Participants: 1.5 mg/kg Emicizumab QW |
|---|---|
| 1 to 12 Weeks | 6.2 (2.35 to 13.40) |
| 13 to 24 Weeks | 3.4 (0.78 to 9.29) |
| 25 to 36 Weeks | 1.5 (0.11 to 6.40) |
| 37 to 48 Weeks | 1.4 (0.09 to 6.29) |
| 49 to 60 Weeks | 1.1 (0.04 to 5.74) |
| 61 to 72 Weeks | 1.0 (0.02 to 5.53) |
| 73 to 84 Weeks | 1.3 (0.07 to 6.12) |
| 85 to 96 Weeks | 1.0 (0.02 to 5.56) |
| 97 to 108 Weeks | 1.2 (0.05 to 5.86) |
| 109 to 120 Weeks | 0.9 (0.01 to 5.34) |
| 121 to 132 Weeks | 0.8 (0.01 to 5.20) |
| 133 to 144 Weeks | 0.5 (0.00 to 4.62) |
| 145 to 156 Weeks | 0.8 (0.01 to 5.29) |
| 157 to 168 Weeks | 0.3 (0.00 to 4.31) |
| 169 to 180 Weeks | 0.8 (0.01 to 5.14) |
| 181 to 192 Weeks | 0.2 (0.00 to 4.15) |
| 193 to 204 Weeks | 0.0 (NA to 3.69) |
| 205 to 216 Weeks | 0.0 (NA to 3.69) |
| 217 to 228 Weeks | 0.0 (NA to 3.69) |
| 229 to 240 Weeks | 0.0 (NA to 3.69) |
The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
| all bleeds per year | All Participants: 1.5 mg/kg Emicizumab QW |
|---|---|
| 1 to 12 Weeks | 0.0 (0.00 to 8.70) |
| 13 to 24 Weeks | 0.0 (0.00 to 4.35) |
| 25 to 36 Weeks | 0.0 (0.00 to 0.00) |
| 37 to 48 Weeks | 0.0 (0.00 to 0.00) |
| 49 to 60 Weeks | 0.0 (0.00 to 0.00) |
| 61 to 72 Weeks | 0.0 (0.00 to 0.00) |
| 73 to 84 Weeks | 0.0 (0.00 to 0.00) |
| 85 to 96 Weeks | 0.0 (0.00 to 0.00) |
| 97 to 108 Weeks | 0.0 (0.00 to 0.00) |
| 109 to 120 Weeks | 0.0 (0.00 to 0.00) |
| 121 to 132 Weeks | 0.0 (0.00 to 0.00) |
| 133 to 144 Weeks | 0.0 (0.00 to 0.00) |
| 145 to 156 Weeks | 0.0 (0.00 to 0.00) |
| 157 to 168 Weeks | 0.0 (0.00 to 0.00) |
| 169 to 180 Weeks | 0.0 (0.00 to 0.00) |
| 181 to 192 Weeks | 0.0 (0.00 to 0.00) |
| 193 to 204 Weeks | 0.0 (0.00 to 0.00) |
| 205 to 216 Weeks | 0.0 (0.00 to 0.00) |
| 217 to 228 Weeks | 0.0 (0.00 to 0.00) |
| 229 to 240 Weeks | 0.0 (0.00 to 0.00) |
The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
| treated spontaneous bleeds per year | All Participants: 1.5 mg/kg Emicizumab QW |
|---|---|
| 1 to 12 Weeks | 2.2 (0.31 to 7.56) |
| 13 to 24 Weeks | 1.3 (0.06 to 6.04) |
| 25 to 36 Weeks | 0.4 (0.00 to 4.45) |
| 37 to 48 Weeks | 0.2 (0.00 to 4.04) |
| 49 to 60 Weeks | 0.1 (0.00 to 3.96) |
| 61 to 72 Weeks | 0.2 (0.00 to 4.05) |
| 73 to 84 Weeks | 0.2 (0.00 to 4.08) |
| 85 to 96 Weeks | 0.1 (0.00 to 3.92) |
| 97 to 108 Weeks | 0.3 (0.00 to 4.34) |
| 109 to 120 Weeks | 0.0 (NA to 3.69) |
| 121 to 132 Weeks | 0.1 (0.00 to 3.89) |
| 133 to 144 Weeks | 0.0 (NA to 3.69) |
| 145 to 156 Weeks | 0.4 (0.00 to 4.53) |
| 157 to 168 Weeks | 0.2 (0.00 to 4.01) |
| 169 to 180 Weeks | 0.2 (0.00 to 4.08) |
| 181 to 192 Weeks | 0.0 (NA to 3.69) |
| 193 to 204 Weeks | 0.0 (NA to 3.69) |
| 205 to 216 Weeks | 0.0 (NA to 3.69) |
| 217 to 228 Weeks | 0.0 (NA to 3.69) |
| 229 to 240 Weeks | 0.0 (NA to 3.69) |
The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants whose dose was up-titrated, the efficacy period ended the day before the first day on the up-titrated dose.
| treated spontaneous bleeds per year | All Participants: 1.5 mg/kg Emicizumab QW |
|---|---|
| 1 to 12 Weeks | 0.0 (0.00 to 0.00) |
| 13 to 24 Weeks | 0.0 (0.00 to 0.00) |
| 25 to 36 Weeks | 0.0 (0.00 to 0.00) |
| 37 to 48 Weeks | 0.0 (0.00 to 0.00) |
| 49 to 60 Weeks | 0.0 (0.00 to 0.00) |
| 61 to 72 Weeks | 0.0 (0.00 to 0.00) |
| 73 to 84 Weeks | 0.0 (0.00 to 0.00) |
| 85 to 96 Weeks | 0.0 (0.00 to 0.00) |
| 97 to 108 Weeks | 0.0 (0.00 to 0.00) |
| 109 to 120 Weeks | 0.0 (0.00 to 0.00) |
| 121 to 132 Weeks | 0.0 (0.00 to 0.00) |
| 133 to 144 Weeks | 0.0 (0.00 to 0.00) |
| 145 to 156 Weeks | 0.0 (0.00 to 0.00) |
| 157 to 168 Weeks | 0.0 (0.00 to 0.00) |
| 169 to 180 Weeks | 0.0 (0.00 to 0.00) |
| 181 to 192 Weeks | 0.0 (0.00 to 0.00) |
| 193 to 204 Weeks | 0.0 (0.00 to 0.00) |
| 205 to 216 Weeks | 0.0 (0.00 to 0.00) |
| 217 to 228 Weeks | 0.0 (0.00 to 0.00) |
| 229 to 240 Weeks | 0.0 (0.00 to 0.00) |
Investigators sought information on adverse events (AEs) at each contact with participants. The WHO toxicity grading scale was used for assessing AE severity (i.e., intensity of an AE); any AEs not specifically listed in the WHO toxicity grading scale were assessed for severity according to the following grades: Grade 1 is mild; Grade 2 is moderate, Grade 3 is severe; Grade 4 is life-threatening; and Grade 5 is death. Regardless of severity, some AEs may have also met seriousness criteria. The terms "severe" and "serious" are not synonymous; severity and seriousness were independently assessed for each AE. For participants whose emicizumab dose was up-titrated, only data before up-titration is included. aPCC = activated prothrombin complex concentrate; Hypersens.= hypersensitivity
| Participants | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis | Arm B (Emi): 1.5 mg/kg Emicizumab QW | Arm C: 1.5 mg/kg Emicizumab QW | Arm D: 1.5 mg/kg Emicizumab QW |
|---|---|---|---|---|---|
| Any Adverse Event (AE) | 34 | 9 | 15 | 46 | 9 |
| AE with Fatal Outcome | 0 | 0 | 0 | 1 | 0 |
| Serious AE | 10 | 4 | 4 | 9 | 2 |
| AE Leading to Withdrawal from Treatment | 2 | 0 | 0 | 1 | 0 |
| AE Leading to Dose Mod./Interruption | 1 | 0 | 0 | 5 | 0 |
| Grade ≥3 AE | 10 | 4 | 3 | 7 | 3 |
| Related AE | 15 | 0 | 4 | 13 | 4 |
| Local Injection Site Reaction | 9 | 0 | 3 | 7 | 4 |
| Systemic Hypersens./Anaphylac(tic/toid) Reaction | 0 | 0 | 0 | 0 | 0 |
| Thrombotic Microangiopathy (TMA) | 1 | 0 | 0 | 2 | 0 |
| TMA Event Related to aPCC and Emicizumab | 1 | 0 | 0 | 2 | 0 |
| Thromboembolic Event (TE) | 1 | 1 | 1 | 1 | 0 |
| TE Event Related to aPCC and Emicizumab | 1 | 0 | 0 | 1 | 0 |
'Total ADA Negative' is the sum of all subjects who tested negative for ADA in the 2 following categories: 'ADA Negative', those who are pre-dose ADA negative or are missing pre-dose ADA data and who have all negative post-dose ADA results; and 'ADA Negative (Treatment Unaffected)', a subset who are pre-dose ADA positive but do not have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement. 'Total ADA Positive' is the sum of all subjects who tested positive for ADA in the 2 following categories: 'ADA Positive (Treatment Boosted)', those who are pre-dose ADA positive and have a ≥4-fold increase in post-dose ADA levels compared to baseline measurement; and 'ADA Positive (Treatment Induced)', those who are pre-dose ADA negative or missing data and who have at least one post-dose ADA positive sample. ADA-positive samples were further analyzed for neutralizing capacity using a modified FVIII chromogenic assay; if also positive, they were considered neutralizing ADAs.
| Participants | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Emi): 1.5 mg/kg Emicizumab QW | Arm C: 1.5 mg/kg Emicizumab QW | Arm D: 1.5 mg/kg Emicizumab QW |
|---|---|---|---|---|
| Total ADA Negative (Neg+Neg Unaffected) | 33 | 18 | 47 | 11 |
| ADA Negative, Negative | 33 | 17 | 46 | 11 |
| ADA Negative, Negative (Treatment Unaffected) | 0 | 1 | 1 | 0 |
| Total ADA Positive (Boosted + Induced) | 0 | 0 | 2 | 0 |
| ADA Positive, Positive (Treatment Boosted) | 0 | 0 | 0 | 0 |
| ADA Positive, Positive (Treatment Induced) | 0 | 0 | 2 | 0 |
| ADA Positive with Neutralizing ADAs | 0 | 0 | 2 | 0 |
Plasma concentrations of emicizumab were analyzed using a validated Enzyme Linked Immunosorbent Assay (ELISA). The lower limit of quantification (LLOQ) was 100 nanograms per milliliter (ng/mL). Because participants in Arm B switched from episodic bypassing agents to start receiving emicizumab prophylaxis after Week 24, the timepoints for Arm B (Emi) are expressed relative to first emicizumab dose.
| micrograms per milliliter (mcg/mL) | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Emi): 1.5 mg/kg Emicizumab QW | Arm C: 1.5 mg/kg Emicizumab QW | Arm D: 1.5 mg/kg Emicizumab QW | All Participants: 1.5 mg/kg Emicizumab QW |
|---|---|---|---|---|---|
| Week 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Week 2 | 16.2 ± 4.4 | 21.7 ± 10.6 | 15.8 ± 5.5 | 18.3 ± 6.5 | 17.1 ± 6.6 |
| Week 3 | 31.6 ± 7.3 | 32.3 ± 10.4 | 31.7 ± 8.3 | 32.7 ± 13.0 | 31.9 ± 8.8 |
| Week 4 | 43.8 ± 12.2 | 44.6 ± 18.6 | 44.7 ± 11.5 | 49.0 ± 13.5 | 44.9 ± 13.2 |
| Week 5 | 53.5 ± 15.1 | 52.2 ± 14.2 | 54.0 ± 13.2 | 59.1 ± 14.6 | 54.1 ± 14.0 |
| Week 7 | 52.8 ± 16.2 | 53.3 ± 18.0 | 53.6 ± 14.3 | 54.9 ± 9.2 | 53.4 ± 14.9 |
| Week 9 | 50.4 ± 12.4 | 48.9 ± 16.7 | 52.6 ± 15.7 | 53.7 ± 13.8 | 51.5 ± 14.7 |
| Week 13 | 49.3 ± 13.4 | 45.2 ± 16.2 | 52.6 ± 15.0 | 53.4 ± 14.0 | 50.5 ± 14.7 |
| Week 17 | 50.7 ± 15.0 | 46.5 ± 17.4 | 51.2 ± 14.9 | 57.5 ± 16.9 | 51.0 ± 15.6 |
| Week 21 | 52.6 ± 17.4 | 44.5 ± 15.4 | 51.6 ± 17.1 | 55.0 ± 13.7 | 51.1 ± 16.6 |
| Week 25 | 54.6 ± 19.1 | 45.8 ± 18.6 | 50.4 ± 16.8 | 52.8 ± 14.1 | 51.2 ± 17.6 |
| Week 33 | 50.7 ± 17.2 | 48.1 ± 21.1 | 54.8 ± 16.7 | 57.1 ± 15.2 | 52.7 ± 17.5 |
| Week 41 | 45.3 ± 13.7 | 49.3 ± 25.9 | 54.8 ± 23.4 | 63.3 ± 19.4 | 52.0 ± 21.6 |
| Week 49 | 48.0 ± 12.3 | 54.6 ± 27.6 | 56.1 ± 22.2 | 55.1 ± 18.7 | 53.3 ± 20.5 |
| Week 61 | 52.2 ± 16.3 | 51.8 ± 33.4 | 60.9 ± 27.7 | 53.2 ± 13.8 | 56.0 ± 24.8 |
| Week 73 | 55.5 ± 14.9 | 45.6 ± 26.2 | 62.9 ± 24.9 | 51.9 ± 13.0 | 57.1 ± 22.0 |
| Week 85 | 56.9 ± 18.3 | 42.5 ± 34.4 | 56.6 ± 22.7 | 50.9 ± 12.5 | 54.5 ± 22.7 |
| Week 97 | 53.2 ± 15.2 | 34.4 ± 26.4 | 54.6 ± 20.0 | 53.8 ± 16.9 | 51.3 ± 19.9 |
| Week 109 | 49.6 ± 15.9 | 32.8 ± 31.4 | 47.4 ± 12.4 | 49.3 ± 12.8 | 46.7 ± 17.6 |
| Week 121 | 53.8 ± 16.3 | 36.1 ± 33.6 | 46.3 ± 12.5 | 53.1 ± 5.0 | 48.5 ± 19.7 |
| Week 133 | 50.5 ± 15.9 | 48.7 ± 29.4 | 49.0 ± 18.5 | 52.0 ± NA | 49.8 ± 18.8 |
| Week 145 | 51.3 ± 16.6 | 38.2 ± 19.0 | 44.0 ± 21.7 | 49.5 ± 10.3 | 47.4 ± 17.4 |
| Week 157 | 58.0 ± 16.5 | — | 45.5 ± 17.0 | 55.4 ± 19.2 | 55.3 ± 16.7 |
| Week 169 | 55.0 ± 19.3 | — | 43.2 ± 20.2 | 50.8 ± NA | 52.5 ± 18.7 |
Collected over From Baseline until study completion (median [min-max] safety observation period for all participants: 133.97 [0.1-249.1] weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: 1.5 mg/kg Emicizumab QW | 0/34 (0%) | 11/34 (32.4%) | 33/34 (97.1%) |
| Arm B (Control): No Prophylaxis | 0/18 (0%) | 5/18 (27.8%) | 9/18 (50%) |
| Arm B (Emi): 1.5 mg/kg Emicizumab QW | 0/18 (0%) | 4/18 (22.2%) | 15/18 (83.3%) |
| Arm C: 1.5 mg/kg Emicizumab QW | 1/49 (2%) | 9/49 (18.4%) | 42/49 (85.7%) |
| Arm D: 1.5 mg/kg Emicizumab QW | 0/11 (0%) | 2/11 (18.2%) | 9/11 (81.8%) |
| Event | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis | Arm B (Emi): 1.5 mg/kg Emicizumab QW | Arm C: 1.5 mg/kg Emicizumab QW | Arm D: 1.5 mg/kg Emicizumab QW |
|---|---|---|---|---|---|
| HaemarthrosisMusculoskeletal and connective tissue disorders | 2/34 | 2/18 | 1/18 | 2/49 | 0/11 |
| Tooth development disorderGastrointestinal disorders | 0/34 | 0/18 | 0/18 | 0/49 | 1/11 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/34 | 0/18 | 0/18 | 0/49 | 1/11 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/34 | 1/18 | 0/18 | 0/49 | 0/11 |
| Device related infectionInfections and infestations | 0/34 | 1/18 | 0/18 | 1/49 | 0/11 |
| Urinary tract infectionInfections and infestations | 0/34 | 1/18 | 0/18 | 0/49 | 0/11 |
| HaematuriaRenal and urinary disorders | 0/34 | 1/18 | 0/18 | 1/49 | 0/11 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/34 | 0/18 | 1/18 | 0/49 | 0/11 |
| HaematomaVascular disorders | 0/34 | 0/18 | 1/18 | 0/49 | 0/11 |
| Large intestine polypGastrointestinal disorders | 0/34 | 0/18 | 1/18 | 0/49 | 0/11 |
| Event | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis | Arm B (Emi): 1.5 mg/kg Emicizumab QW | Arm C: 1.5 mg/kg Emicizumab QW | Arm D: 1.5 mg/kg Emicizumab QW |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 11/34 | 2/18 | 7/18 | 16/49 | 2/11 |
| Injection site reactionGeneral disorders | 9/34 | 0/18 | 3/18 | 8/49 | 4/11 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/34 | 0/18 | 6/18 | 12/49 | 3/11 |
| HeadacheNervous system disorders | 6/34 | 1/18 | 4/18 | 13/49 | 3/11 |
| Upper respiratory tract infectionInfections and infestations | 8/34 | 2/18 | 2/18 | 7/49 | 2/11 |
| InfluenzaInfections and infestations | 1/34 | 0/18 | 2/18 | 10/49 | 0/11 |
| ToothacheGastrointestinal disorders | 4/34 | 0/18 | 2/18 | 2/49 | 2/11 |
| Skin abrasionInjury, poisoning and procedural complications | 1/34 | 0/18 | 0/18 | 0/49 | 2/11 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/34 | 0/18 | 0/18 | 0/49 | 2/11 |
| HypertensionVascular disorders | 5/34 | 0/18 | 0/18 | 3/49 | 2/11 |
All enrolled participants
| Age, Continuous(years) | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis, Then Emicizumab | Arm C: 1.5 mg/kg Emicizumab QW | Arm D: 1.5 mg/kg Emicizumab QW | Total |
|---|---|---|---|---|---|
| Mean | 35.8 ± 13.9 | 37.2 ± 13.7 | 25.6 ± 16.8 | 39.0 ± 16.1 | 31.9 ± 16.2 |
| Age, Customized(Participants) | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis, Then Emicizumab | Arm C: 1.5 mg/kg Emicizumab QW | Arm D: 1.5 mg/kg Emicizumab QW | Total |
|---|---|---|---|---|---|
| Adolescents (12-17 years) | 4 | 2 | 26 | 0 | 32 |
| Adults (18-64 years) | 30 | 15 | 21 | 10 | 76 |
| Elderly (65-84 years) | 1 | 1 | 2 | 1 | 5 |
| Sex: Female, Male(Participants) | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis, Then Emicizumab | Arm C: 1.5 mg/kg Emicizumab QW | Arm D: 1.5 mg/kg Emicizumab QW | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 35 | 18 | 49 | 11 | 113 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis, Then Emicizumab | Arm C: 1.5 mg/kg Emicizumab QW | Arm D: 1.5 mg/kg Emicizumab QW | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 1 | 12 | 1 | 18 |
| Not Hispanic or Latino | 31 | 17 | 37 | 10 | 95 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis, Then Emicizumab | Arm C: 1.5 mg/kg Emicizumab QW | Arm D: 1.5 mg/kg Emicizumab QW | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 10 | 3 | 8 | 0 | 21 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 4 | 4 | 3 | 0 | 11 |
| White | 21 | 10 | 33 | 11 | 75 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 4 | 0 | 4 |
| Number of Participants by the Number of Bleeds (<9 or ≥9) in the Last 24 Weeks Prior to Study Entry(Participants) | Arm A: 1.5 mg/kg Emicizumab QW | Arm B (Control): No Prophylaxis, Then Emicizumab | Arm C: 1.5 mg/kg Emicizumab QW | Arm D: 1.5 mg/kg Emicizumab QW | Total |
|---|---|---|---|---|---|
| <9 Bleeds | 11 | 5 | 23 | 6 | 45 |
| ≥9 Bleeds | 24 | 13 | 26 | 5 | 68 |
Ran from Nov 2015 to primary completion in Oct 2016, 11 months.
Results were first posted in Nov 2017, 1 year after primary completion.
Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 11 months is below that.
Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emicizumab